Tag Archives: pharmaceutical costs
Deborah Gleeson and Ronald Labonté object to lengthening market exclusivity for biologic medicines in the United States-Mexico-Canada Agreement.
Marc-André Gagnon dispels misconceptions about the benefits of private health insurance plans and argues in favour of a universal model for pharmacare.
Andrea Frydl cautions Canadians about the harms of direct-to-consumer advertising for pharmaceuticals and offers advice for health care providers and policy makers.
Steve Morgan gives us four reasons to support universal pharmacare and then invites us to sign the Parliamentary Petition e-959 (Health care services).
Matthew Herder argues that recent drug price hikes are only one part of a bigger problem with industry-driven pharmaceutical research and development.